WHO ICTRP trial
A randomized, double blind, placebo controlled multicenter dose ranging study to…
NL-OMON48764 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON48764 |
|---|---|
| Public title | A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis |
| Scientific title | A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis - CZPL389A2203 (ZEST) |
| Primary sponsor | Novartis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Canada;Finland;Germany;Iceland;Japan;Netherlands;Poland;United Kingdom;United States of America |
| Conditions | atopic eczema Neurodermitis;10014982;atopic eczema;Neurodermitis |
| Interventions | Four dose levels were chosen to characterize the dose-response curve. An unbalanced allocation of 2:1:1:2:2 for placebo: 3 mg: 10 mg: 30 mg: 50 mg with more subjects on placebo and the higher doses of ZPL389 is chosen to increase the… |
| Registration date | Mar 6, 2019 |
| Target size | 25 |
| Secondary IDs | 2017-002176-75;NCT03517566;NL63968.078.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: